Publications by authors named "Markolf Hanefeld"

Claim this Profile
R
Rivaroxaban compared with low-dose aspirin in individuals with type 2 diabetes and high cardiovascular risk: a randomised trial to assess effects on endothelial function, platelet activation and vascular biomarkers.
Frank Pistrosch, Jan B Matschke, Dorothea Schipp, Bernhard Schipp, Elena Henkel, Markolf Hanefeld

Diabetologia· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Prospective Studies of Atherosclerosis (Proof-ATHERO) Consortium: Design and Rationale.
Lena Tschiderer, Lisa Seekircher, Gerhard Klingenschmid, Raffaele Izzo, Damiano Baldassarre, Markolf Hanefeld

Gerontology· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Not Available].
Markolf Hanefeld, Michael Zitzmann, Eberhard Nieschlag

Dtsch Med Wochenschr· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial.
Harpreet S Bajaj, Hertzel C Gerstein, Purnima Rao-Melacini, Jan Basile, Helen Colhoun, Markolf Hanefeld

Lancet Diabetes Endocrinol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Current and Potential Therapeutic Use of Metformin-The Good Old Drug.
Józef Drzewoski, Markolf Hanefeld

Pharmaceuticals (Basel)· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Remission of type 2 diabetes following long-term treatment with injectable testosterone undecanoate in patients with hypogonadism and type 2 diabetes: 11-year data from a real-world registry study.
Karim Sultan Haider, Ahmad Haider, Farid Saad, Gheorghe Doros, Markolf Hanefeld

Diabetes Obes Metab· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rationale for Timely Insulin Therapy in Type 2 Diabetes Within the Framework of Individualised Treatment: 2020 Update.
Markolf Hanefeld, Holger Fleischmann, Thorsten Siegmund, Jochen Seufert

Diabetes Ther· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial.
Hertzel C Gerstein, Robert Hart, Helen M Colhoun, Rafael Diaz, Mark Lakshmanan, Markolf Hanefeld

Lancet Diabetes Endocrinol· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.
Hertzel C Gerstein, Helen M Colhoun, Gilles R Dagenais, Rafael Diaz, Mark Lakshmanan, Markolf Hanefeld

Lancet· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
Hertzel C Gerstein, Helen M Colhoun, Gilles R Dagenais, Rafael Diaz, Mark Lakshmanan, Markolf Hanefeld

Lancet· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Intravenous Ferric Carboxymaltose in Patients with Type 2 Diabetes Mellitus and Iron Deficiency: CLEVER Trial Study Design and Protocol.
Christoph Schindler, Andreas L Birkenfeld, Markolf Hanefeld, Ulrike Schatz, Carsta Köhler

Diabetes Ther· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Remission of type 2 diabetes and pleiotropic effects of long-term testosterone treatment for "late-onset" hypogonadism: A case report.
Ahmad Haider, Karim Haider, Farid Saad, Markolf Hanefeld

SAGE Open Med Case Rep· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The anorexigenic peptide neurotensin relates to insulin sensitivity in obese patients after BPD or RYGB metabolic surgery.
Christian von Loeffelholz, Lidia Castagneto Gissey, Tina Schumann, Christine Henke, Anica Kurzbach, Markolf Hanefeld

Int J Obes (Lond)· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sudomotor Testing of Diabetes Polyneuropathy.
Sarah-Maria Krieger, Manja Reimann, Rocco Haase, Elena Henkel, Markolf Hanefeld

Front Neurol· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intravenous Ferric Carboxymaltose in Patients with Type 2 Diabetes Mellitus and Iron Deficiency: CLEVER Trial Study Design and Protocol.
Christoph Schindler, Andreas L Birkenfeld, Markolf Hanefeld, Ulrike Schatz, Carsta Köhler

Diabetes Ther· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide.
Hertzel C Gerstein, Helen M Colhoun, Gilles R Dagenais, Rafael Diaz, Mark Lakshmanan, Markolf Hanefeld

Diabetes Obes Metab· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A review of glucagon-like peptide-1 receptor agonists and their effects on lowering postprandial plasma glucose and cardiovascular outcomes in the treatment of type 2 diabetes mellitus.
David R Owens, Louis Monnier, Markolf Hanefeld

Diabetes Obes Metab· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment.
Markolf Hanefeld, Juan M Arteaga, Lawrence A Leiter, Giulio Marchesini, Elena Nikonova

Diabetes Obes Metab· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intra-individual variability and circadian rhythm of vascular endothelial growth factors in subjects with normal glucose tolerance and type 2 diabetes.
Markolf Hanefeld, Katrin Engelmann, Dieter Appelt, Dirk Sandner, Ingo Weigmann

PLoS One· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. Diabetes Care 2016;39:2026-2035.
Julio Rosenstock, Ronnie Aronson, George Grunberger, Markolf Hanefeld, PierMarco Piatti

Diabetes Care· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The use of lipid-lowering therapy and effects of antihyperglycaemic therapy on lipids in subjects with type 2 diabetes with or without cardiovascular disease: a pooled analysis of data from eleven randomized trials with insulin glargine 100 U/mL.
Markolf Hanefeld, Louise Traylor, Ling Gao, Wolfgang Landgraf

Cardiovasc Diabetol· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitus.
Markolf Hanefeld, Denis Raccah, Louis Monnier

Expert Opin Drug Metab Toxicol· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comment on Ferrannini et al. CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis. Diabetes Care 2016;39:1108-1114.
Jens Jordan, Ali El-Armouche, Markolf Hanefeld, Stefan R Bornstein, Andreas L Birkenfeld

Diabetes Care· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial.
Julio Rosenstock, Ronnie Aronson, George Grunberger, Markolf Hanefeld, PierMarco Piatti

Diabetes Care· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolic Vascular Syndrome: New Insights into a Multidimensional Network of Risk Factors and Diseases.
Gerhard H Scholz, Markolf Hanefeld

Visc Med· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis